F Dx Advisors, Inc. Amgen Inc Transaction History

F Dx Advisors, Inc.

$659 Million
Q1 2024

A detailed history of F Dx Advisors, Inc. transactions in Amgen Inc stock. As of the latest transaction made, F Dx Advisors, Inc. holds 3,518 shares of AMGN stock, worth $1.09 Million. This represents 0.15% of its overall portfolio holdings.

Number of Shares

3,518

Previous 7,607 53.75%

Holding current value

$1.09 Million

Previous $2.19 Million 54.36%

% of portfolio

0.15%

Previous 0.17%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 03, 2024	SELL	$268.87 - $324.56 $1.1 Million - $1.33 Million	-4,089 Reduced 53.75%	3,518 $1 Million
Q4 2023 Feb 12, 2024	SELL	$255.7 - $288.46 $29,916 - $33,749	-117 Reduced 1.51%	7,607 $2.19 Million
Q3 2023 Nov 02, 2023	SELL	$218.65 - $271.46 $495,460 - $615,128	-2,266 Reduced 22.68%	7,724 $2.08 Million
Q2 2023 Jul 17, 2023	BUY	$214.27 - $253.37 $1.31 Million - $1.55 Million	6,102 Added 156.94%	9,990 $2.22 Million
Q4 2022 Feb 09, 2023	SELL	$229.03 - $291.01 $615,632 - $782,234	-2,688 Reduced 40.88%	3,888 $1.02 Million

Q3 2022 Nov 10, 2022	SELL	$224.46 - $253.15 $41,974 - $47,339	-187 Reduced 2.77%	6,576 $1.48 Million
Q2 2022 Aug 03, 2022	BUY	$230.71 - $256.74 $1.03 Million - $1.14 Million	4,449 Added 192.26%	6,763 $1.65 Million
Q1 2022 May 03, 2022	SELL	$219.27 - $242.57 $1.02 Million - $1.13 Million	-4,645 Reduced 66.75%	2,314 $560,000
Q4 2021 Feb 01, 2022	SELL	$198.88 - $227.6 $3.14 Million - $3.59 Million	-15,769 Reduced 69.38%	6,959 $1.57 Million
Q3 2021 Oct 08, 2021	BUY	$212.27 - $248.7 $363,618 - $426,023	1,713 Added 8.15%	22,728 $4.83 Million
Q2 2021 Aug 05, 2021	BUY	$233.58 - $259.14 $570,402 - $632,819	2,442 Added 13.15%	21,015 $5.12 Million
Q1 2021 Apr 14, 2021	BUY	$221.91 - $258.6 $3.1 Million - $3.61 Million	13,952 Added 301.93%	18,573 $4.62 Million
Q1 2021 Apr 13, 2021	SELL	$221.91 - $258.6 $3.61 Million - $4.21 Million	-16,278 Reduced 77.89%	4,621 $1.15 Million
Q4 2020 Feb 08, 2021	BUY	$216.38 - $257.67 $244,509 - $291,167	1,130 Added 5.72%	20,899 $4.81 Million
Q3 2020 Nov 12, 2020	SELL	$234.65 - $260.95 $135,862 - $151,090	-579 Reduced 2.85%	19,769 $5.02 Million
Q2 2020 Jul 22, 2020	SELL	$197.81 - $242.74 $314,913 - $386,442	-1,592 Reduced 7.26%	20,348 $4.8 Million
Q1 2020 May 22, 2020	SELL	$182.24 - $241.7 $24.3 Million - $32.3 Million	-133,554 Reduced 85.89%	21,940 $4.45 Million
Q1 2020 May 13, 2020	BUY	$182.24 - $241.7 $24.7 Million - $32.8 Million	135,735 Added 686.95%	155,494 $1.29 Million
Q4 2019 Feb 12, 2020	BUY	$189.21 - $243.2 $647,098 - $831,744	3,420 Added 20.93%	19,759 $4.76 Million
Q3 2019 Nov 07, 2019	SELL	$174.11 - $208.62 $2.33 Million - $2.79 Million	-13,384 Reduced 45.03%	16,339 $3.16 Million
Q2 2019 Jul 19, 2019	BUY	$166.7 - $195.41 $21,170 - $24,817	127 Added 0.43%	29,723 $5.48 Million
Q1 2019 May 14, 2019	BUY	$180.87 - $203.88 $614,234 - $692,376	3,396 Added 12.96%	29,596 $5.62 Million
Q4 2018 Apr 29, 2019	SELL	$178.4 - $208.25 $8.87 Million - $10.4 Million	-49,715 Reduced 65.49%	26,200 $5.1 Million
Q4 2018 Feb 07, 2019	BUY	$178.4 - $208.25 $5.32 Million - $6.21 Million	29,804 Added 64.64%	75,915 $14.8 Million
Q3 2018 Nov 13, 2018	SELL	$185.29 - $208.89 $107,653 - $121,365	-581 Reduced 1.24%	46,111 $9.56 Million
Q2 2018 Aug 08, 2018	BUY	$166.05 - $186.51 $627,835 - $705,194	3,781 Added 8.81%	46,692 $8.62 Million
Q1 2018 May 02, 2018	SELL	$169.43 - $198.0 $1.7 Million - $1.99 Million	-10,031 Reduced 18.95%	42,911 $7.32 Million
Q4 2017 Feb 09, 2018	BUY	$168.79 - $188.59 $103,974 - $116,171	616 Added 1.18%	52,942 $9.21 Million
Q3 2017 Nov 03, 2017	BUY	$167.29 - $191.0 $241,399 - $275,613	1,443 Added 2.84%	52,326 $9.76 Million
Q2 2017 Aug 11, 2017	BUY	N/A	50,883	50,883 $8.76 Million

Others Institutions Holding AMGN

# of Institutions

2,933

Shares Held

401M

Call Options Held

6.59M

Put Options Held

6.6M

View Full List

About AMGEN INC

Ticker AMGN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 534,931,008
Market Cap $165B
Description
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...

More about AMGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of F Dx Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on F Dx Advisors, Inc. with notifications on news.

Account